Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib in Chinese Patients with 131I-Refractory Differentiated Thyroid Cancer
NCT02966093Phase 3Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Jan 2017
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of lenvatinib in differentiated thyroid cancer (DTC), sponsored by Eisai Co., Ltd.. Started Jan 2017; status: completed.
02
Drugs
lenvatinib
03
Conditions
differentiated thyroid cancer (DTC)
Beyond the preview
Go deeper on NCT02966093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02966093.